Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Payables (2023 - 2025)

Historic Payables for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $17.9 million.

  • Monte Rosa Therapeutics' Payables rose 1856.41% to $17.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.9 million, marking a year-over-year increase of 1856.41%. This contributed to the annual value of $18.8 million for FY2024, which is 2866.44% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Payables stood at $17.9 million for Q3 2025, which was up 1856.41% from $13.8 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Payables high stood at $18.8 million for Q4 2024, and its period low was $10.2 million during Q1 2023.
  • Its 3-year average for Payables is $14.1 million, with a median of $14.2 million in 2023.
  • Its Payables has fluctuated over the past 5 years, first surged by 458.85% in 2024, then surged by 5203.02% in 2025.
  • Monte Rosa Therapeutics' Payables (Quarter) stood at $14.6 million in 2023, then grew by 28.66% to $18.8 million in 2024, then dropped by 4.7% to $17.9 million in 2025.
  • Its Payables stands at $17.9 million for Q3 2025, versus $13.8 million for Q2 2025 and $16.3 million for Q1 2025.